NCT05575440

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

Evaluation of F-18 Tetrafluoroborate (18F-TFB) PET/CT in Patients With Differentiated Thyroid Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 24 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.

Detailed description

PRIMARY OBJECTIVES: I. Evaluate fluorine F 18 tetrafluoroborate (18F-TFB) positron emission tomography (PET)/computed tomography (CT) imaging in patients with intermediate or high risk differentiated thyroid cancer (DTC) and compare to the current clinical standard. II. Assess the impact of 18F-TFB PET/CT on clinical management. OUTLINE: Patients receive fluorine F 18 tetrafluoroborate intravenously (IV) and undergo PET/CT scan on study.

Conditions

• Differentiated Thyroid Gland Carcinoma
• Thyroid Gland Follicular Carcinoma
• Thyroid Gland Papillary Carcinoma

Interventions

Type	Name	Description
PROCEDURE	Computed Tomography	Undergo a PET/CT scan
RADIATION	Fluorine F 18 Tetrafluoroborate	Given IV
PROCEDURE	Positron Emission Tomography	Undergo a PET/CT scan
OTHER	Survey Administration	Ancillary studies

Timeline

• Start date: 2022-04-22
• Primary completion: 2028-05-01
• Completion: 2028-05-01
• First posted: 2022-10-12
• Last updated: 2026-02-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study